Fairbanks Capital Management Inc. lifted its stake in Allergan PLC. (NYSE:AGN) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,480 shares of the company’s stock after purchasing an additional 70 shares during the period. Allergan PLC. accounts for about 1.2% of Fairbanks Capital Management Inc.’s investment portfolio, making the stock its 20th biggest holding. Fairbanks Capital Management Inc.’s holdings in Allergan PLC. were worth $1,332,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Crestwood Advisors Group LLC bought a new stake in shares of Allergan PLC. in the first quarter worth approximately $103,000. Feltz Wealth PLAN Inc. bought a new stake in Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp lifted its holdings in Allergan PLC. by 62.7% during the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after purchasing an additional 178 shares in the last quarter. Jacobi Capital Management LLC lifted its holdings in Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors lifted its holdings in Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after purchasing an additional 12 shares in the last quarter. 82.06% of the stock is owned by institutional investors.
A number of research analysts have weighed in on AGN shares. Cowen and Company set a $400.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, June 8th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Mizuho lowered their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Cantor Fitzgerald began coverage on shares of Allergan PLC. in a research report on Friday, June 16th. They set a “neutral” rating and a $231.00 price target for the company. Finally, Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $275.49.
Allergan PLC. (NYSE:AGN) traded down 1.73% during mid-day trading on Tuesday, reaching $223.78. The company’s stock had a trading volume of 1,338,498 shares. The company has a market capitalization of $74.81 billion, a PE ratio of 6.82 and a beta of 1.18. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The firm has a 50 day moving average price of $238.12 and a 200-day moving average price of $237.88.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.35 EPS. On average, equities analysts predict that Allergan PLC. will post $16.27 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is currently 9.95%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.